Aidixi® is the domestic commercial brand name of Disitamab Vedotin For Injection, a domestically developed HER2-targeted antibody-drug conjugate (ADC) independently researched and developed by RemeGen. It consists of a humanized anti-HER2 monoclonal antibody conjugated with MMAE via a cleavable linker.…
Trodelvy® is the international commercial brand name of Sacituzumab Govitecan for Injection, marketed domestically under the Chinese brand name Tuodavi® and developed by Gilead Sciences. It is a Trop-2 targeted antibody-drug conjugate (ADC). The antibody specifically binds to Trop-2 on…
SULANDA® is the commercial brand name of Surufatinib Capsules, an oral small-molecule multi-target tyrosine kinase inhibitor independently developed by HUTCHMED. It inhibits VEGFR, FGFR and CSF-1R simultaneously, exerting dual anti-angiogenic and immune-modulating anti-tumor effects. Main IndicationsMonotherapy for unresectable locally advanced…
Carteyva® is the international commercial brand name of Relmacabtagene Autoleucel Injection, domestically marketed under the Chinese brand name Beinuoda®. It is an autologous CD19-targeted CAR-T cell immunotherapy developed by JW Therapeutics. Patient-derived T cells are genetically modified ex vivo to…
Conmana® is the commercial brand name of Icotinib Hydrochloride Tablets, an orally administered epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) independently developed in China. It selectively inhibits EGFR tyrosine kinase activity, blocks downstream signal transduction, and suppresses proliferation and…
Airuini® is the domestic commercial brand name of Pyrotinib Maleate Tablets, an oral irreversible pan-HER tyrosine kinase inhibitor independently developed by Jiangsu Hengrui Pharmaceuticals. It inhibits EGFR, HER2 and HER4 simultaneously, blocks downstream oncogenic signaling pathways, and suppresses proliferation of…
AiRuiKa® is the commercial brand name of Camrelizumab for Injection, a humanized anti-programmed death 1 (anti-PD-1) monoclonal antibody independently developed by Jiangsu Hengrui Pharmaceuticals. It binds to the PD-1 receptor on T lymphocytes, blocks its binding to PD-L1/PD-L2 on tumor…
HIBRUKA® is the international commercial brand name of Orelabrutinib Tablets, an orally active, irreversible Bruton’s tyrosine kinase (BTK) inhibitor developed by Innocare. It covalently binds to BTK, inhibiting B-cell receptor signaling and thereby suppressing the proliferation and survival of malignant…
Tyvyt® is the commercial brand name of Sintilimab Injection, a fully human anti-programmed death 1 (anti-PD-1) monoclonal antibody developed by Innovent Biologics and Eli Lilly. It binds to the PD-1 receptor on T cells, blocking its interaction with PD-L1/PD-L2 to…
Symbiox® is the commercial brand name of Benvitimod Cream, a topical immunomodulatory agent developed by Sino Biopharmaceutical. It acts as a selective inhibitor of the phosphodiesterase 4 (PDE4) enzyme, reducing pro-inflammatory cytokine production and inflammation in the skin. Main IndicationsTopical…